Keywords: new, data, show, merck, sharp, dohme, cozaar
New data show Merck Sharp and Dohme's Cozaar to be cost-effective
Article | 28 June 2004
Data presented at the European Society of Hypertension meeting in Paris, France, have revealed the cost-effectiveness of Merck Sharp & Dohme's ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
